Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Ravi KalhanDavid SladeRiju RayChad MoretzGuillaume GermainFrançois LalibertéQin ShenMei Sheng DuhSean Dale MacKnightBeth HahnPublished in: International journal of chronic obstructive pulmonary disease (2021)
These findings suggest that high-cost, high-comorbidity patients with COPD receiving UMEC/VI compared with FP/SAL, B/F, and TIO as IMT may have lower medical costs and exacerbation risk.